A dimorphism in the 3’-untranslated region of the prothrombin gene (G to A transition at position 20210) has recently been reported to be associated with increases in plasma prothrombin levels and in the risk of venous thrombosis (1). We have examined the prothrombin dimorphism among 99 unselected outpatients with phlebography verified deep venous thrombosis, and in 282 healthy controls. The prevalence of the 20210 A allele was 7.1% (7/99) in the patient group, and 1.8% (5/282) in the healthy control group (p = 0.0095). The relative risk of venous thrombosis was calculated to be 4.2 (95% Cl, 1.3 to 13.6), and was still significant when adjustment was made for age, sex and the factor V:R506Q mutation causing APC resistance [odds ratio 3.8 (95% Cl, 1.1 13.2)]. As previously reported, 28% of the patients were carriers of the factor V:R506Q mutation. Thus, 34% (one patient carried both traits) of unselected patients with deep venous thrombosis were carriers of an inherited prothrombotic disorder. To sum up, our results confirm the 20210 A allele of the prothrombin gene to be an important risk factor for venous thrombosis.
References
1
Poort SW,
Rosendaal FR,
Reitsma PH,
Bertina RM.
A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703
4
Haverkate F,
Samama M.
Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC subcommittee on Fibrinogen. Thromb Haemost 1995; 73: 151-161
5
Heijboer H,
Brandjes D,
Büller HR.
et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-1516
7
Dahlbäck B,
Carlsson M,
Svensson PJ.
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
8
Bertina RM,
Koeleman BPC,
Koster T,
Rosendaal FR,
Dirven RJ,
de RondeH,
van der VeldenPA,
Reitsma PH.
Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
10
Voorberg J,
Roelse J,
Koopman R,
Büller H,
Berends F,
ten Cate JW,
Mertens K,
van Mourik JA.
Association of idiopathic thromboembolism with single point mutation at Arg506 of factor V. Lancet 1994; 343: 1535-1536
11
Zӧller B,
Dahlbäck B.
Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1996; 343: 1536-1538
12
Griffin JH,
Evatt BL,
Wideman C,
Fernandez JA.
Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 1993; 82: 1989-1993
17
Jackson CM.
Physiology and biochemistry of prothrombin. In: Haemostasis and Thrombosis.
Bloom AL,
Forbes CD,
Thomas DP,
Tuddenham EGD.
eds. Churchill Livingstone; Edinburgh, UK: 1994. pp 397-438
18
Bertina RM,
van TilburgNH,
de Fouw NJ,
Haverkate F.
Thrombin, a link between coagulation activation and fibrinolysis. Ann NY Acad Sci 1992; 667: 239-248
19
Dang QD,
Vindigni A,
Di Cera E.
An allosteric switch controls the procoagulant and anticoagulant activities of thrombin. Proc Natl Acad Sci USA 1995; 92: 5977-5981
20
Svensson PJ,
Zöller B,
Mattiasson I,
Dahlbäck B.
The factor V:R506Q mutation causing APC resistance is highly prevalent among unselected outpatients with clinically suspected deep venous thrombosis. J Intern Med 1997; 241: 379-386
21
Zöller B,
Svensson PJ,
He X,
Dahlbäck B.
Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524
22
Zӧller B,
Holm J,
Svensson PJ,
Dahlbäck B.
Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with inherited APCresistance and/or protein S deficiency. Thromb Haemost 1996; 75: 270-274
23
Simioni P,
Scarano L,
Gavasso S,
Sardella C,
Girolami B,
Scudeller A,
Girolami A.
Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC-resistance due to factor V Leiden mutation. Br J Haematol 1996; 92: 435-441
